Free Trial

Sarepta Therapeutics (SRPT) Competitors

Sarepta Therapeutics logo
$17.93 -0.72 (-3.86%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$18.54 +0.61 (+3.37%)
As of 05:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SRPT vs. CTMX, EDIT, GRFS, ABVX, RYTM, LEGN, CYTK, AXSM, NUVL, and CRSP

Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Grifols (GRFS), Abivax (ABVX), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), Nuvalent (NUVL), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry.

Sarepta Therapeutics vs. Its Competitors

Sarepta Therapeutics (NASDAQ:SRPT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Sarepta Therapeutics has higher revenue and earnings than CytomX Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$2.48B0.71$235.24M-$0.87-20.61
CytomX Therapeutics$138.10M2.52$31.87M$0.563.77

Sarepta Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500.

In the previous week, CytomX Therapeutics had 11 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 19 mentions for CytomX Therapeutics and 8 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.78 beat CytomX Therapeutics' score of 0.53 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sarepta Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CytomX Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 7.6% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CytomX Therapeutics has a net margin of 34.04% compared to Sarepta Therapeutics' net margin of -2.34%. CytomX Therapeutics' return on equity of 158.70% beat Sarepta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sarepta Therapeutics-2.34% -1.03% -0.37%
CytomX Therapeutics 34.04%158.70%36.04%

Sarepta Therapeutics currently has a consensus price target of $39.32, indicating a potential upside of 119.30%. CytomX Therapeutics has a consensus price target of $5.42, indicating a potential upside of 156.71%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics
6 Sell rating(s)
14 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.10
CytomX Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

Summary

CytomX Therapeutics beats Sarepta Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRPT vs. The Competition

MetricSarepta TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.82B$3.16B$5.76B$10.51B
Dividend YieldN/A2.36%5.53%4.57%
P/E Ratio-20.6121.0476.0626.61
Price / Sales0.71252.06472.8291.51
Price / Cash7.6646.3537.4661.85
Price / Book1.129.7813.586.45
Net Income$235.24M-$52.73M$3.29B$271.57M
7 Day Performance5.16%3.16%1.83%2.61%
1 Month Performance-11.33%4.69%4.02%7.28%
1 Year Performance-85.71%16.37%77.05%29.60%

Sarepta Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRPT
Sarepta Therapeutics
4.3468 of 5 stars
$17.93
-3.9%
$39.32
+119.3%
-85.6%$1.82B$2.48B-20.611,372Analyst Upgrade
Gap Up
CTMX
CytomX Therapeutics
4.2069 of 5 stars
$1.99
-0.5%
$5.75
+188.9%
+83.5%$328.17M$138.10M3.55170News Coverage
Analyst Forecast
Analyst Revision
EDIT
Editas Medicine
3.8637 of 5 stars
$2.67
-0.7%
$5.10
+91.0%
-17.8%$240.09M$32.31M-0.94230
GRFS
Grifols
3.9122 of 5 stars
$9.63
-2.5%
$10.30
+7.0%
+11.9%$6.62B$7.45B8.2323,822Positive News
Gap Up
ABVX
Abivax
2.8083 of 5 stars
$85.87
+2.2%
$99.43
+15.8%
+655.2%$6.49BN/A0.0061
RYTM
Rhythm Pharmaceuticals
3.206 of 5 stars
$96.03
-0.2%
$101.57
+5.8%
+93.3%$6.38B$130.13M-31.90140Positive News
LEGN
Legend Biotech
3.1544 of 5 stars
$33.88
+2.3%
$74.22
+119.1%
-28.3%$6.25B$627.24M-38.502,609Positive News
CYTK
Cytokinetics
4.2401 of 5 stars
$49.44
-3.3%
$75.38
+52.5%
-6.8%$5.92B$18.47M-9.69250Trending News
Analyst Forecast
AXSM
Axsome Therapeutics
4.849 of 5 stars
$116.78
-1.4%
$177.86
+52.3%
+29.1%$5.83B$385.69M-23.03380Insider Trade
NUVL
Nuvalent
2.9686 of 5 stars
$79.37
-1.4%
$120.91
+52.3%
-20.5%$5.72BN/A-16.2040
CRSP
CRISPR Therapeutics
3.2349 of 5 stars
$57.84
+2.8%
$71.60
+23.8%
+30.0%$5.26B$37.31M-10.65460Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SRPT) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners